Green tea extract tested for cancer survivor stress relief
NCT ID NCT07220447
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether L-theanine, a natural substance found in green tea, can help cancer patients who have finished treatment feel more relaxed and improve their mood. Researchers will enroll 50 adults to find the best dose and see if it's practical to use. The goal is to ease stress and anxiety during the surveillance period after cancer treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative. * Assent, when appropriate, will be obtained per institutional guidelines * Willingness to comply with all study interventions including the use of L-theanine and follow-up assessments * Age: ≥ 18 years * Ability to read and understand English or Spanish for questionnaires * Patients must be a cancer patient who has completed treatment and has been in surveillance for at least 6 months * Participants must not have used any herbs or supplements in the past 30 days * Participants must report an anxiety score of \> 3 on Visual Analog Scale - Anxiety * Participants must not have had any changes to their psychiatric medications within the past 60 days * Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 month after the last dose of protocol therapy. * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only) Exclusion Criteria: * Concurrent use of other alternative medicines, including herbal agents and high-dose vitamins and minerals, unless taken to correct a documented vitamin or mineral insufficiency * Chemotherapy, radiation therapy, biological therapy, immunotherapy, or any other systemic treatment excluding hormonal therapy (must be on a stable dose of hormonal therapy for at least 60 days) * Any patients taking bortezomib, as L-theanine can decrease effectiveness * Any patients currently enrolled in other clinical trials that might interfere with the results of this study * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent * Any patients with an ongoing active/unstable psychiatric condition, depressive/bi-polar related disorders, anxiety, psychosis disorders, or substance use that may interfere with the ability to participate in the study as outlined in the study procedures section of the protocol * Any patients with chronically unstable blood pressure or chronic low blood pressure * Diagnosis of Gilbert's disease * Females only: Pregnant or breastfeeding * Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphatic system neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
City of Hope Seacliff
NOT_YET_RECRUITINGHuntington Beach, California, 92648, United States
-
City of Hope at Irvine Lennar
NOT_YET_RECRUITINGIrvine, California, 92618, United States
-
City of Hope at Irvine Sand Canyon
NOT_YET_RECRUITINGIrvine, California, 92618, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine stop GI cancers from returning?
- Can a phone app help childhood cancer survivors keep track of their health?
- Can the way we word cancer research invitations boost participation?
- A chill pill for Chemo's side effects? cooling therapy and a Blood-Flow drug take on nerve pain
- Wearable tech could spot Post-Surgery problems early
- Can an AI chatbot ease the aftermath of cancer?